Literature DB >> 10684270

Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes.

W Popik1, P M Pitha.   

Abstract

Binding of human immunodeficiency virus type 1 (HIV-1) to CD4 receptors induces multiple cellular signaling pathways, including the MEK/ERK cascade. While the interaction of X4 HIV-1 with CXCR4 does not seem to activate this pathway, viruses using CCR5 for entry efficiently activate MEK/ERK kinases (W. Popik, J. E. Hesselgesser, and P. M. Pitha, J. Virol. 72:6406-6413, 1998; W. Popik and P. M. Pitha, Virology 252:210-217, 1998). Since the importance of MEK/ERK in the initial steps of viral replication is poorly understood, we have examined the role of MEK/ERK signaling in the CD3- and CD28 (CD3/CD28)-mediated activation of HIV-1 replication in resting peripheral blood CD4(+) T lymphocytes infected with X4 or R5 HIV-1. We have found that the MEK/ERK inhibitor U0126 selectively inhibited CD3/CD28-stimulated replication of X4 HIV-1, while it did not affect the replication of R5 HIV-1. Inhibition of the CD3/CD28-stimulated MEK/ERK pathway did not affect the formation of the early proviral transcripts in cells infected with either X4 or R5 HIV-1, indicating that virus reverse transcription is not affected in the absence of MEK/ERK signaling. In contrast, the levels of nuclear provirus in cells infected with X4 HIV-1, detected by the formation of circular proviral DNA, was significantly lower in cells stimulated in the presence of MEK/ERK inhibitor than in the absence of the inhibitor. However, in cells infected with R5 HIV-1, the inhibition of the MEK/ERK pathway did not affect nuclear localization of the proviral DNA. These data suggest that the nuclear import of X4, but not R5, HIV-1 is dependent on a CD3/CD28-stimulated MEK/ERK pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684270      PMCID: PMC111744          DOI: 10.1128/jvi.74.6.2558-2566.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Multiple p21ras effector pathways regulate nuclear factor of activated T cells.

Authors:  E Genot; S Cleverley; S Henning; D Cantrell
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

2.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

3.  Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.

Authors:  E Vicenzi; P P Bordignon; P Biswas; A Brambilla; C Bovolenta; M Cota; F Sinigaglia; G Poli
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 4.  T cell antigen receptor signal transduction pathways.

Authors:  D Cantrell
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

5.  Nuclear import of HIV-1 DNA in resting CD4+ T cells requires a cyclosporin A-sensitive pathway.

Authors:  Y Sun; L M Pinchuk; M B Agy; E A Clark
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

6.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

7.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA.

Authors:  A G Bukrinskaya; A Ghorpade; N K Heinzinger; T E Smithgall; R E Lewis; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  20 in total

1.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication.

Authors:  Claudia Cicala; James Arthos; Sara M Selig; Glynn Dennis; Douglas A Hosack; Donald Van Ryk; Marion L Spangler; Tavis D Steenbeke; Prateeti Khazanie; Neil Gupta; Jun Yang; Marybeth Daucher; Richard A Lempicki; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway.

Authors:  Nancy Q Liu; Albert S Lossinsky; Waldemar Popik; Xia Li; Chandrasekhar Gujuluva; Benjamin Kriederman; Jaclyn Roberts; Tatania Pushkarsky; Michael Bukrinsky; Marlys Witte; Martin Weinand; Milan Fiala
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

3.  R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.

Authors:  Claudia Cicala; James Arthos; Elena Martinelli; Nina Censoplano; Catherine C Cruz; Eva Chung; Sara M Selig; Donald Van Ryk; Jun Yang; Shyla Jagannatha; Tae Wook Chun; Ping Ren; Richard A Lempicki; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

4.  HIV-1 Exploits a Dynamic Multi-aminoacyl-tRNA Synthetase Complex To Enhance Viral Replication.

Authors:  Alice A Duchon; Corine St Gelais; Nathan Titkemeier; Joshua Hatterschide; Li Wu; Karin Musier-Forsyth
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

5.  Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways.

Authors:  Cheryl Twu; Nancy Q Liu; Waldemar Popik; Michael Bukrinsky; James Sayre; Jaclyn Roberts; Shammas Rania; Vishnu Bramhandam; Kenneth P Roos; W Robb MacLellan; Milan Fiala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-11       Impact factor: 11.205

6.  Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

Authors:  A J Marozsan; V S Torre; M Johnson; S C Ball; J V Cross; D J Templeton; M E Quiñones-Mateu; R E Offord; E J Arts
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Non-productive HIV-1 infection of human glomerular and urinary podocytes.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  Virology       Date:  2010-12-05       Impact factor: 3.616

8.  Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.

Authors:  Waldemar Popik; Timothy M Alce; Wei-Chun Au
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

10.  Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.

Authors:  Renate R König; Egbert Flory; Stefanie Steidl; Jeanette Neumann; Cheick Coulibaly; Edgar Holznagel; Silke Holzammer; Stephen Norley; Klaus Cichutek
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.